107 related articles for article (PubMed ID: 1711542)
1. An acquired antithrombin autoantibody directed toward the catalytic center of the enzyme.
Sié P; Bezeaud A; Dupouy D; Archipoff G; Freyssinet JM; Dugoujon JM; Serre G; Guillin MC; Boneu B
J Clin Invest; 1991 Jul; 88(1):290-6. PubMed ID: 1711542
[TBL] [Abstract][Full Text] [Related]
2. Partial characterization of an autoantibody recognizing the secondary binding site(s) of thrombin in a patient with recurrent spontaneous arterial thrombosis.
Costa JM; Fiessinger JN; Capron L; Aiach M
Thromb Haemost; 1992 Feb; 67(2):193-9. PubMed ID: 1320300
[TBL] [Abstract][Full Text] [Related]
3. Bothrojaracin: a potent two-site-directed thrombin inhibitor.
Arocas V; Zingali RB; Guillin MC; Bon C; Jandrot-Perrus M
Biochemistry; 1996 Jul; 35(28):9083-9. PubMed ID: 8703912
[TBL] [Abstract][Full Text] [Related]
4. Autoantibodies to thrombin directed against both of its cryptic exosites.
Mollica L; Preston RJ; Chion AC; Lees SJ; Collins P; Lewis S; Lane DA
Br J Haematol; 2006 Feb; 132(4):487-93. PubMed ID: 16412021
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V following exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function.
Chouhan VD; De La Cadena RA; Nagaswami C; Weisel JW; Kajani M; Rao AK
Thromb Haemost; 1997 Feb; 77(2):343-9. PubMed ID: 9157594
[TBL] [Abstract][Full Text] [Related]
6. Ecotin modulates thrombin activity through exosite-2 interactions.
Castro HC; Monteiro RQ; Assafim M; Loureiro NI; Craik C; Zingali RB
Int J Biochem Cell Biol; 2006; 38(11):1893-900. PubMed ID: 16843700
[TBL] [Abstract][Full Text] [Related]
7. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
Lämmle B; Griffin JH
Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
[TBL] [Abstract][Full Text] [Related]
8. Role of Leu99 of thrombin in determining the P2 specificity of serpins.
Rezaie AR
Biochemistry; 1997 Jun; 36(24):7437-46. PubMed ID: 9200692
[TBL] [Abstract][Full Text] [Related]
9. Human alpha-thrombin inhibition by the active site titrant N alpha-(N,N-dimethylcarbamoyl)-alpha-azalysine p-nitrophenyl ester: a comparative kinetic and X-ray crystallographic study.
Nardini M; Pesce A; Rizzi M; Casale E; Ferraccioli R; Balliano G; Milla P; Ascenzi P; Bolognesi M
J Mol Biol; 1996 May; 258(5):851-9. PubMed ID: 8637015
[TBL] [Abstract][Full Text] [Related]
10. Generation and mechanism of action of a potent inhibitor of factor XIII function.
Reed GL; Lukacova D
Thromb Haemost; 1995 Aug; 74(2):680-5. PubMed ID: 8585006
[TBL] [Abstract][Full Text] [Related]
11. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
12. Allosteric effects of a monoclonal antibody against thrombin exosite II.
Colwell NS; Blinder MA; Tsiang M; Gibbs CS; Bock PE; Tollefsen DM
Biochemistry; 1998 Oct; 37(43):15057-65. PubMed ID: 9790668
[TBL] [Abstract][Full Text] [Related]
13. Allosteric changes of thrombin catalytic site induced by interaction of bothrojaracin with anion-binding exosites I and II.
Monteiro RQ; Rapôso JG; Wisner A; Guimarães JA; Bon C; Zingali RB
Biochem Biophys Res Commun; 1999 Sep; 262(3):819-22. PubMed ID: 10471408
[TBL] [Abstract][Full Text] [Related]
14. Contribution of lysine 60f to S1' specificity of thrombin.
Rezaie AR; Olson ST
Biochemistry; 1997 Feb; 36(5):1026-33. PubMed ID: 9033392
[TBL] [Abstract][Full Text] [Related]
15. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Schumacher WA; Steinbacher TE; Heran CL; Seiler SM; Michel IM; Ogletree ML
J Pharmacol Exp Ther; 1993 Dec; 267(3):1237-42. PubMed ID: 8263785
[TBL] [Abstract][Full Text] [Related]
16. A synthetic analog of fibrinogen alpha 27-50 is an inhibitor of thrombin.
Binnie CG; Lord ST
Thromb Haemost; 1991 Feb; 65(2):165-8. PubMed ID: 2053103
[TBL] [Abstract][Full Text] [Related]
17. Energetics of thrombin-thrombomodulin interaction.
Vindigni A; White CE; Komives EA; Di Cera E
Biochemistry; 1997 Jun; 36(22):6674-81. PubMed ID: 9184147
[TBL] [Abstract][Full Text] [Related]
18. The effects of human thrombomodulin on the inactivation of thrombin by its serum inhibitors.
Thompson EA; Salem HH
Thromb Haemost; 1987 Oct; 58(3):806-10. PubMed ID: 2829375
[TBL] [Abstract][Full Text] [Related]
19. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
Turk B; Brieditis I; Bock SC; Olson ST; Björk I
Biochemistry; 1997 Jun; 36(22):6682-91. PubMed ID: 9184148
[TBL] [Abstract][Full Text] [Related]
20. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
Elgue G; Blombäck M; Olsson P; Riesenfeld J
Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
